Calls
1
u/HopefulChain7006
Reddit r/pennystocks
Win Rate
100.0%
return
+180.8%
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Jan 14
$3.02
+180.8%
The author views IBRX as a long-term hold of at least 2–3 years rather than a swing trade, citing ImmunityBio's commercial-stage ANKTIVA bladder cancer therapy and positive results. Near-term catalysts include EU/UK approval decisions for ANKTIVA plus BCG in non-muscle invasive bladder cancer, continued U.S. commercial growth with reimbursement in place, Phase 3 NSCLC enrollment completion expected in early 2026, and possible ASCO/AACR data updates. Stated risks are heavy reliance on ANKTIVA, major U.S. lung cancer approval depending on Phase 3 data not expected until 2027, biotech/regulatory volatility, and potential dilution given the company's debt.
Pharma & Biotech
Showing 1 of 1 calls · sorted by mentions
Choose a mentions count to open ticker posts.
u/HopefulChain7006 has 1 trade ideas tracked on Buzzberg across 1 tickers since January 2026. Most covered: IBRX.
Historical call returns are modeled from recorded ideas and stored prices, not actual brokerage portfolio returns. Check the evaluated call set and horizon; past results do not establish future prediction accuracy. Explore our data and methodology
